Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Active not recruiting 3Unknown 1Recruiting 1

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 57Immunoglobulin Light-chain Amyloidosis 5Smoldering Multiple Myeloma 4Plasmacytoma 3Leukemia, Plasma Cell 3Renal Insufficiency 1Recurrence 1POEMS Syndrome 1Chromosome 17 deletion 1Anemia 1Amyloidosis 1

Interventions

Dexamethasone 50Melphalan 29Cyclophosphamide 25Bortezomib 24Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8fludarabine phosphate 7ixazomib 6dexamethasone 21-phosphate 6Whole-Body Irradiation 6Mycophenolic Acid 6venetoclax 5birtamimab 5auricularum 5Thalidomide 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Busulfan 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Biopsy 4sargramostim 3miridesap 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × auricularum × Plasma cell × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Emory University

Phase 1 Active not recruiting
11 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡